Preclinical data confirm the unique specificity and disease-modifying potential of Alzinova’s monoclonal antibody, ALZ-201
Alzinova AB (publ) (FN STO: ALZ), a Swedish biopharma company developing treatments of Alzheimer’s disease by specifically targeting neurotoxic amyloid-β (Aβ) oligomers, today announces that a research project evaluating Alzinova’s monoclonal antibody, ALZ-201, has been successfully completed in collaboration with Amsterdam University Medical Centers. Data from the project confirm the unique specificity and preclinical efficacy of ALZ-201 and the related clinical-stage vaccine ALZ-101.The collaborative project evaluated Alzinova’s monoclonal antibody, ALZ-201, as a potential novel therapy